NEW YORK (GenomeWeb) – Australian diagnostics firm SpeeDx has received CE marking for an assay to detect resistant strains of Mycoplasma genitalium, the company announced today.

The ResistancePlus MG assay detects M. genitalium as well as mutations in the bacterium's 23S rRNA that confer resistance to the macrolide drug azithromycin.

"As with the better known STD, gonorrhea, M. genitalium has developed serious treatment challenges because of the recent rise of antibiotic resistance," Colin Denver, SpeeDx's CEO, noted in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.